文献速递儿童心血管与肾脏

儿童SSNS利妥昔单抗后维持治疗:左旋咪唑与霉酚酸酯疗效对比

[Efficacy analysis of maintenance therapy with levamisole compared to mycophenolate mofetil after rituximab treatment in children].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2026-01-01

该回顾性队列研究纳入42例接受利妥昔单抗治疗的激素敏感型肾病综合征患儿,比较B细胞重建后序贯左旋咪唑或霉酚酸酯维持治疗的疗效与安全性。结果显示霉酚酸酯组复发次数更少、无复发生存率更高、年复发率更低,两组不良反应发生率无显著差异。

要点

  • 利妥昔单抗后序贯霉酚酸酯维持治疗,复发次数显著低于左旋咪唑组。
  • 霉酚酸酯组无复发生存率更高、无复发生存时间更长、年复发率更低。
  • 两组治疗后激素累积剂量及累积住院次数均较治疗前下降,不良反应无差异。

核心结论

  • 与左旋咪唑相比,利妥昔单抗治疗后序贯霉酚酸酯是维持激素敏感型肾病综合征患儿疾病缓解的更优选择。

研究设计与样本

  • 回顾性队列研究,纳入2023年3月至2024年5月郑州大学附属儿童医院肾脏风湿免疫科接受利妥昔单抗治疗的42例激素敏感型肾病综合征患儿。
  • 根据B细胞重建后序贯药物分为左旋咪唑组和霉酚酸酯组,每组各21例。
  • 比较两组治疗前后复发次数、糖皮质激素累积用量、累计住院次数及治疗后1年内复发相关指标和不良反应。

主要发现

  • 利妥昔单抗治疗后1年,左旋咪唑组和霉酚酸酯组复发次数均较治疗前显著下降(均P<0.001)。
  • 左旋咪唑组治疗后复发次数显著高于霉酚酸酯组,无复发生存率显著低于霉酚酸酯组,无复发生存时间明显短于霉酚酸酯组,年复发率显著高于霉酚酸酯组(均P<0.05)。
  • 两组治疗后激素累积剂量及累积住院次数均低于治疗前(均P<0.05)。
  • 两组不良反应发生率比较差异无统计学意义(P>0.05)。

关键数值与推荐

  • 左旋咪唑组治疗前后复发次数:0.0(0.0,1.0)比1.0(1.0,2.0)次/年,Z=4.24,P<0.001。
  • 霉酚酸酯组治疗前后复发次数:0.0(0.0,0.0)比1.0(1.0,2.0)次/年,Z=4.88,P<0.001。
  • 左旋咪唑组治疗后复发次数显著高于霉酚酸酯组,年复发率显著高于霉酚酸酯组(均P<0.05)。
  • 两组不良反应发生率差异无统计学意义(P>0.05)。

临床怎么用

  • 对于接受利妥昔单抗治疗的激素敏感型肾病综合征患儿,B细胞重建后可优先考虑序贯霉酚酸酯而非左旋咪唑进行维持治疗,以降低复发风险。

局限性

  • 本研究为单中心回顾性队列研究,样本量较小(42例),结论需更大规模前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the efficacy and safety of levamisole(LEV) versus mycophenolate mofetil(MMF) as maintenance therapy following rituximab treatment in children with steroid-sensitive nephrotic syndrome(SSNS). Methods: This was a retrospective cohort study. Clinical data were collected form 42 children with SSNS treated with RTX at the Department of Nephrology, Rheumatology and Immunology at the Children's Hospital Affiliated to Zhengzhou University between March 2023 and May 2024. Based on the sequential maintenance medication administered after B-cell reconstitution, the patients were assigned to 2 groups: the LEV group and the MMF group. The number of disease relapses, cumulative dosage of glucocorticoid and cumulative hospitalization times were compared between the 2 groups before and after treatment. The 2 groups were compared regarding the number of recurrences within 1 year after RTX treatment, time to the first recurrence, annual recurrence rate, cumulative glucocorticoid dose, cumulative number of hospitalizations, as well as the occurrence of adverse reactions. Intergroup comparisons were made using the Mann-Whitney U test, χ2 test or Fisher exact test, as appropriate. Recurrence-free survival curves were plotted using the Kaplan-Meier method. Results: A total of 42 pediatric patients were enrolled, comprising 37 males and 5 females. The age of disease onset was 4.3 (3.0,6.3) years. There were 21 patients in the LEV group and 21 in the MMF group. Within 1 year after RTX treatment, the recurrence times decreased significantly in both the LEV group and the MMF group (0.0(0.0, 1.0) vs. 1.0(1.0, 2.0), 0.0(0.0, 0.0) vs. 1.0(1.0, 2.0) times/year, Z=4.24, 4.88, both P<0.001). Furthermore, the recurrence times after treatment was significantly higher in the LEV group than in the MMF group (P<0.05). Patients in the LEV group exhibited a significantly lower recurrence-free survival rate and a shorter recurrence-free survival time compared to those in the MMF group, along with a higher annual recurrence rate (all P<0.05). Furthermore, both the cumulative glucocorticoid dose and the cumulative number of hospitalizations decreased significantly after treatment in each group compared to baseline (all P<0.05). The 2 groups showed no significant difference in the incidence of adverse reactions (P>0.05). Conclusion: Sequential therapy with MMF after RTX treatment represents a more favorable option than LEV for maintaining disease remission in children with SSNS. 目的: 探讨左旋咪唑(LEV)与霉酚酸酯(MMF)在利妥昔单抗(RTX)治疗激素敏感型肾病综合征(SSNS)患儿后维持治疗的有效性与安全性。 方法: 回顾性队列研究。选择2023年3月至2024年5月于郑州大学附属儿童医院肾脏风湿免疫科接受RTX治疗的42例SSNS患儿的临床资料,根据B细胞重建后序贯药物不同分为LEV组和MMF组。比较两组患儿RTX治疗前后疾病复发次数、糖皮质激素累积用量及累计住院次数;治疗后1年内复发次数、首次复发时间、年复发率、糖皮质激素累积剂量、累积住院次数、不良反应等指标。组间比较采用Mann-Whitney U检验、χ2检验或Fisher确切概率法,采用Kaplan-Meier法绘制生存曲线。 结果: 42例患儿中男37例、女5例,起病年龄4.3(3.0,6.3)岁,LEV组和MMF组各21例。RTX治疗后1年LEV组和MMF组复发次数均较治疗前下降[0.0(0.0,1.0)比1.0(1.0,2.0),0.0(0.0,0.0)比1.0(1.0,2.0)次/年,Z=4.24、4.88,均P<0.001],LEV组治疗后复发次数显著高于MMF组,无复发生存率显著低于MMF组,无复发生存时间明显短于MMF组,年复发率显著高于MMF组(均P<0.05)。两组患儿治疗后激素累积剂量及累积住院次数均低于治疗前(均P<0.05)。两组患儿不良反应发生率比较差异无统计学意义(P>0.05)。 结论: 与LEV相比,RTX治疗后序贯MMF是维持SSNS患儿疾病缓解的更优选择。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. He QQ, Zhao GP, Li JT, et al. [Efficacy analysis of maintenance therapy with levamisole compared to mycophenolate mofetil after rituximab treatment in children]. Zhonghua Er Ke Za Zhi. 2026. PMID: 41986267. doi:10.3760/cma.j.cn112140-20251208-01085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。